Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia
Key facts
- Who runs it
- Instituto de Investigación Biomédica de Salamanca
- Where
- Spain3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 350 people, planned
- Started
- 9 Jun 2026
- Expected to end
- Jan 2029
- Type of study
- Observational
- Treatments tested
- Plasma and DNA sample collection for proteomic and genomic analysis
- Record updated
- 15 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Adults (≥18 years)
- Written informed consent provided by patient or legal representative
- Diagnosis of hematologic malignancy under induction chemotherapy, post-allogeneic hematopoietic stem cell transplantation, or CAR-T therapy
- High-risk febrile neutropenia (ANC ≤ 100 cells/mm³, expected duration ≥ 7 days, or significant comorbidities)
- Fever defined as oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour
- Hospitalized or requiring immediate admission at the time of FN diagnosis; ´- Initial uncomplicated clinical presentation, with no previous infection or colonization by multidrug-resistant bacteria
- Eligible for initial monotherapy with broad-spectrum empirical antibiotic
- Availability for serial plasma sampling and clinical follow-up
Who cannot take part
- Any condition preventing safe participation or reliable sample collection
- Age <18 years
- Low-risk FN according to MASCC/CISNE criteria
- Initial sample collected after antibiotic administration
- Decline or inability to provide informed consent
- Fever induced by noninfectious causes (considered as adjustment factor, not exclusion)
This trial is currently available in Spain.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality. Early identification of patients at higher risk of complications such as sepsis or septic shock is critical to optimize antimicrobial management.
Read full original descriptionShow less
This study aims to characterize the human and microbial plasma proteome using high-resolution mass spectrometry to identify biomarker combinations ("combitypes") capable of predicting complications in oncohematologic patients with FN.
A cohort of 350 adult patients with high-risk FN and initially uncomplicated clinical presentation will be enrolled across three tertiary hospitals. Plasma samples will be collected at fever onset (before antibiotic initiation) and after 48 hours. Proteomic data will be integrated with clinical information using multivariate and machine learning models to develop a predictive model for complications.
The group in the trial
- High-risk FN cohort
Adult onco-hematologic inpatients meeting inclusion criteria; two plasma draws at fever onset and 48 h.
Treatment: Plasma and DNA sample collection for proteomic and genomic analysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Prospective Observational Study on the Plasma Proteomic Profiling of Human and Microbial Proteins for the Early Identification of Biomarker Combinations (Combitypes) Associated With Complications in Oncohematologic Patients With Febrile Neutropenia
- Record updated
- 15 June 2026